Twist Bioscience (TWST) Cost of Revenue (2017 - 2026)

Twist Bioscience (TWST) has reported Cost of Revenue for 10 consecutive years, with $53.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cost of Revenue rose 14.6% year-over-year to $53.6 million; the TTM figure through Mar 2026 stood at $196.3 million (up 5.91% YoY), while the FY2025 annual figure was $185.6 million, up 3.31% from the prior year.
• Cost of Revenue advanced to $53.6 million in Q1 2026 per TWST's latest filing, from $49.7 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $53.6 million in Q1 2026 and bottomed at $29.4 million in Q4 2022.
• Historically, Cost of Revenue has averaged $42.1 million across 5 years, with a median of $44.4 million in 2024.
• Annual changes were most pronounced in 2022 — Cost of Revenue surged 56.16% — and 2025, when it fell 3.1%.
• Twist Bioscience's Cost of Revenue stood at $29.4 million in 2022, then soared by 44.47% to $42.5 million in 2023, then advanced by 7.85% to $45.9 million in 2024, then gained by 8.4% to $49.7 million in 2025, then rose by 7.78% to $53.6 million in 2026.
• Business Quant data shows TWST's Cost of Revenue at $53.6 million in Q1 2026, $49.7 million in Q4 2025, and $48.2 million in Q3 2025.